Clinical trials: Prostate Cancer, Castration Resistant
Castration-resistant Prostate Cancer
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma
This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani.
- Trial name
- Apa-CARDIO1 (NCT04567875)
- Testing
- No Intervention on patients
- Where
- 2 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Ospedale Andrea Tortora di Pagani
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Castration Resistant Prostate Cancer
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
The purpose of this study is to find out what effects, good and/or bad,an increased dose of Abiraterone Acetate in combination with prednisone has on patients and their prostate cancer.
- Trial name
- NCT01637402
- Testing
- Abiraterone Acetate, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Terence Friedlander, MD
Metastatic Castration-Resistant Prostate Cancer
Sequencing Abiraterone and Enzalutamide in mCRPC
This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body.
- Trial name
- NCT02125357
- Testing
- Abiraterone acetate, Enzalutamide
- Where
- 7 sites in Canada
- Volunteers
- 202 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Castration Resistant Prostate Cancer
SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation
This study is a multicenter, single arm phase I / II clinical study in mCRPC subjects who failed to receive docetaxel chemotherapy, abitolone acetate and / or enzalutamide (including its analogues) for the treatment of BRCA…
- Trial name
- mCRPC (NCT04486937)
- Testing
- S410914 tablet
- Volunteers
- 90 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy
This trial studies image-guided biopsies work in identifying mechanisms of resistance in participants with castration resistant prostate cancer that has spread to other places in the body and who are undergoing radioligand…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03596710
- Testing
- Image Guided Biopsy
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
This study is a prospective, observational, molecular stratification profiling study. Patients with mCRPC who have received at least one standard treatment for mCRPC will be approached to participate in MAESTRO.
- Trial name
- MAESTRO (NCT03934164)
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Castration-resistant Prostate Cancer
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is…
- Trial name
- PERSEUS1 (NCT03506997)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC
- Trial name
- NCT03137758
- Testing
- PCUR - 101
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pellficure Pharmaceuticals, Inc
Advanced Prostate Cancer, Castration Resistant
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
PROSENZA is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with enzalutamide
- Conditions
- Advanced Prostate Cancer, Castration Resistant, Enzalutamide
- Trial name
- PROSENZA (NCT02922218)
- Where
- 26 sites in Spain
- Volunteers
- 187 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Advanced Prostate Cancer, Castration Resistant
PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.
- Conditions
- Advanced Prostate Cancer, Castration Resistant, Radium 223
- Trial name
- PRORADIUM (NCT02925702)
- Testing
- Radium 223 55mBq/Kg every 4 weeks intravenously
- Where
- 63 sites in Spain
- Volunteers
- 161 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Metastatic Castration Resistant Prostate Cancer
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing…
- Trial name
- MEDI3726 (NCT02991911)
- Testing
- MEDI3726 Post-Chemo, MEDI3726 Pre-Chemo, MEDI3726 & Enzalutamide Combo
- Where
- 5 sites in United States, Switzerland and 1 more
- Volunteers
- 33 people
- Sponsor
- MedImmune LLC
Castration-resistant Prostate Cancer
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.
- Trial name
- BARRIER-P (NCT02429193)
- Testing
- Abiraterone + prednisone, Enzalutamide
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Metastatic Castration-resistant Prostate Cancer
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the…
- Trial name
- NCT04225910
- Testing
- 225Ac-PSMA
- Volunteers
- 20 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Castration-resistant Prostate Cancer
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.
- Trial name
- NCT04188587
- Testing
- 177 Lu-PSMA-I&T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-resistant Prostate Cancer
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
One-arm, multi-center clinical trial of paclitaxel (albumin-binding) combined with carboplatin for castration-resistant prostate cancer
- Trial name
- NCT04148885
- Testing
- nab-paclitaxel, carboplatin
- Volunteers
- 44 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine